October 14, 2020

NIH Paused Eli Lilly Covid-19 Antibody Trial Because Of Safety Concerns-STAT

It could be two weeks until there is news on a paused trial of Eli Lilly’s closely watched monoclonal antibody treatment for Covid-19. The National Institutes of Health said late Tuesday that it paused the trial because one of the two groups in the study — one had received the antibody, the other a placebo — was doing better than the other. Both groups also received remdesivir, a Covid-19 treatment from Gilead Sciences. STAT, 10/13/2020